UY39687A - Anticuerpo monoclonal o fragmento de unión al antígeno del mismo que se une específicamente al gd2 (gangliósido gd2), y uso del mismo - Google Patents

Anticuerpo monoclonal o fragmento de unión al antígeno del mismo que se une específicamente al gd2 (gangliósido gd2), y uso del mismo

Info

Publication number
UY39687A
UY39687A UY0001039687A UY39687A UY39687A UY 39687 A UY39687 A UY 39687A UY 0001039687 A UY0001039687 A UY 0001039687A UY 39687 A UY39687 A UY 39687A UY 39687 A UY39687 A UY 39687A
Authority
UY
Uruguay
Prior art keywords
antigen
binding fragment
specifically binds
monoclonal antibody
ganglioside
Prior art date
Application number
UY0001039687A
Other languages
English (en)
Inventor
Pavel Andreevich Iakovlev
Dmitry Valentinovich Morozov
Sergei Andreevich Ageev
Yulia Sergeevna Chernykh
Diana Aleksandrovna Kondinskaia
Valeriia Evgenevna Shigina
Dina Khaidarovna Sakharova
Mariia Anatolevna Grefenshtein
Alina Konstantinovna Stolyarova
Valery Vladimirovich Solovyev
Original Assignee
Biocad Joint Stock Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from RU2021107773A external-priority patent/RU2796937C2/ru
Application filed by Biocad Joint Stock Co filed Critical Biocad Joint Stock Co
Publication of UY39687A publication Critical patent/UY39687A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3084—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated gangliosides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

La presente invención se refiere al campo de la biotecnología, en particular a un anticuerpo monoclonal o fragmento de unión al antígeno del mismo que se une específicamente al GD2. La invención se refiere además a ácidos nucleicos que codifican dicho anticuerpo, vectores de expresión, células huésped y métodos para producirlos, métodos para producir los anticuerpos según la invención, composiciones farmacéuticas que comprenden el anticuerpo según la invención, composiciones farmacéuticas que comprenden el anticuerpo según la invención y otros compuestos terapéuticamente activos, métodos para tratar enfermedades mediados por GD2, usos de los anticuerpos para tratar enfermedades mediados por GD2.
UY0001039687A 2021-03-24 2022-03-24 Anticuerpo monoclonal o fragmento de unión al antígeno del mismo que se une específicamente al gd2 (gangliósido gd2), y uso del mismo UY39687A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2021107773A RU2796937C2 (ru) 2021-03-24 Моноклональное антитело или его антигенсвязывающий фрагмент, которое специфически связывается с gd2 (ганглиозид gd2), и его применение

Publications (1)

Publication Number Publication Date
UY39687A true UY39687A (es) 2022-08-31

Family

ID=83395963

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001039687A UY39687A (es) 2021-03-24 2022-03-24 Anticuerpo monoclonal o fragmento de unión al antígeno del mismo que se une específicamente al gd2 (gangliósido gd2), y uso del mismo

Country Status (9)

Country Link
CN (1) CN117677695A (es)
AR (1) AR125219A1 (es)
CL (1) CL2023002843A1 (es)
CO (1) CO2023012549A2 (es)
CR (1) CR20230456A (es)
EC (1) ECSP23072412A (es)
TW (1) TW202304989A (es)
UY (1) UY39687A (es)
WO (1) WO2022203552A1 (es)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1706428T3 (pl) * 2004-01-22 2010-02-26 Merck Patent Gmbh Przeciwciała przeciwnowotworowe o zredukowanym wiązaniu dopełniacza
KR101834026B1 (ko) * 2010-06-19 2018-03-02 메모리얼 슬로안-케터링 캔서 센터 항-ｇｄ2 항체
EP2968545B1 (en) * 2013-03-15 2019-03-06 Memorial Sloan Kettering Cancer Center High affinity anti-gd2 antibodies

Also Published As

Publication number Publication date
CO2023012549A2 (es) 2023-10-09
WO2022203552A1 (en) 2022-09-29
CL2023002843A1 (es) 2024-03-22
CR20230456A (es) 2023-12-13
AR125219A1 (es) 2023-06-28
CN117677695A (zh) 2024-03-08
ECSP23072412A (es) 2023-10-31
TW202304989A (zh) 2023-02-01

Similar Documents

Publication Publication Date Title
CO2021006248A2 (es) Anticuerpos anti-nkg2a y usos de los mismos
BR112019008010A2 (pt) anticorpo monoclonal isolado ou fragmento imunologicamente ativo do mesmo, anticorpo monoclonal biespecífico isolado, composição farmacêutica, método para tratamento de uma doença em um sujeito humano em necessidade do mesmo, proteína de fusão, epítopo imunodominante codificado pelo gene cd47, e, molécula biológica
MX2020008795A (es) Anti cuerpos anti tigit y usos de los mismos.
AR126019A1 (es) Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
PE20221580A1 (es) Anticuerpos terapeuticos y sus usos
CL2021000517A1 (es) Anticuerpo etiquetado y/o fragmento del mismo que comprende un anticuerpo monoclonal o un fragmento del mismo, que se une específicamente a tau humano; ácido nucleico que lo codifica; vector; célula; método para producir anticuerpo; y uso de los mismos para inhibir la agregación de tau, y enfermedades asociadas (divisional de la solicitud no. 202001003)
BR112016013347A8 (pt) anticorpo monoclonal humano neutralizante anti-il-33,composição farmacêutica,inibidor da expressão de citocinas,epitopo,molécula de ácido nucleico,vetor,célula hospedeira,método de produção e uso dos mesmos.
BR112015029953A2 (pt) anticorpos anti-tweakr e seus usos
BR112022000371A2 (pt) Anticorpos claudin18 e métodos de tratamento contra câncer
CL2021002792A1 (es) Anticuerpo monoclonal que se une específicamente a gitr
WO2021227307A8 (zh) 抗cd73抗体及其用途
BR112022012474A2 (pt) Anticorpo anti-lilrb1, fragmento de ligação ao antígeno do mesmo, composição farmacêutica que compreende os mesmos, uso do dito anticorpo para tratar ou prevenir um câncer, método de preparar o dito anticorpo, molécula de ácido nucleico e vetor e célula recombinantes.
BR112017027702A2 (pt) anticorpos antirreceptor do fator de crescimento endotelial vascular 2 (vegfr2)
EA202092125A1 (ru) Антитела против рецептора фолата 1 и их применения
BR112022000628A2 (pt) Anticorpos anti-tigit e aplicação dos mesmos
CO2021007053A2 (es) Métodos de tratar la oftalmopatía de graves mediante el uso de anticuerpos anti-fcrn
BR112022025574A2 (pt) Anticorpos que se ligam a cd3, polinucleotídeo isolado, célula hospedeira, método para produzir um anticorpo que se liga a cd3 e para tratar uma doença em um indivíduo, composição farmacêutica, anticorpo para uso e invenção
PE20211792A1 (es) Anticuerpos monoclonales que se unen especificamene a la region beta de la familia trbv-9 del receptor de celulas t humano, y los metodos para su uso
UY39687A (es) Anticuerpo monoclonal o fragmento de unión al antígeno del mismo que se une específicamente al gd2 (gangliósido gd2), y uso del mismo
EA202092122A1 (ru) Антитела против tip-1 и их применения
AR127635A1 (es) ANTICUERPO MONOCLONAL O FRAGMENTO DE UNIÓN A UN ANTÍGENO QUE SE UNE ESPECÍFICAMENTE A LA IL-4Ra, Y USO DEL MISMO
BR112022025020A2 (pt) Dosagem de anticorpos neutralizantes de poliomavírus
ECSP23097121A (es) Anticuerpo biespecífico aislado que se une específicamente a CD47 y PD-L1
AR117072A1 (es) Anticuerpos anti-nkg2a y usos de los mismos
BR112022020716A2 (pt) Anticorpos anti-tumor associados ao antígeno e usos dos mesmos